ArticleJournal of diabetes and metabolic disorders2026
Serum high-density lipoprotein cholesterol uptake capacity and cardiovascular risk in subjects from the Birjand longitudinal aging study.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background-Aim: The ability of high-density lipoprotein (HDL) to remove cholesterol (known as cholesterol efflux efficiency) is crucial in the reverse cholesterol transport pathway and depends on the HDL cholesterol uptake capacity (CUC). CUC represents a novel, faster and simpler assessing HDL functionality that has been suggested as a potential predictor of cardiovascular disease (CVD) risk. Our goal was to explore the correlation between serum CUC and CVD in participants from the Birjand longitudinal aging study (BLAS). Patients-Methods: This cohort study involved 128 CVD patients (mean age 68.3 ± 6.8 years, 43.0% females) and 214 non-CVD individuals (mean age 69.5 ± 6.8 years, 52.3% females) from the BLAS. A refined CUC methodology was employed to assess serum HDL CUC. The connections between CUC and CVD, coronary artery disease (CAD), acute myocardial infarction (AMI), and stroke risk was explored. Results: Serum HDL CUC was non-significantly higher in the non-CVD group compared with CVD patients (1.19 ± 0.58 vs. 1.08 ± 0.42; Conclusions: In this investigation, serum HDL CUC was significantly decreased in stroke patients in comparison to the non-stroke group in a sample from the BLAS. Further studies are necessary to assess the relationships between CUC and CVD risk in several clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.